PL414785A1 - 3-dodecylsulfanyl-butyric acid to be used as a medicine, preferably to prevent development of insulin immunity and the composition containing 3-dodecylsulfanyl-butyric acid as active substance - Google Patents
3-dodecylsulfanyl-butyric acid to be used as a medicine, preferably to prevent development of insulin immunity and the composition containing 3-dodecylsulfanyl-butyric acid as active substanceInfo
- Publication number
- PL414785A1 PL414785A1 PL414785A PL41478515A PL414785A1 PL 414785 A1 PL414785 A1 PL 414785A1 PL 414785 A PL414785 A PL 414785A PL 41478515 A PL41478515 A PL 41478515A PL 414785 A1 PL414785 A1 PL 414785A1
- Authority
- PL
- Poland
- Prior art keywords
- dodecylsulfanyl
- butyric acid
- medicine
- active substance
- composition containing
- Prior art date
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Przedmiotem zgłoszenia jest kwas 3-dodecylosulfanylomasłowy do zastosowania jako lek, zwłaszcza do stosowania w leczeniu i profilaktyce rozwoju insulinooporności. Zgłoszenie dotyczy także kompozycji farmaceutycznej, charakteryzującej się tym, że jako substancję czynną zawiera kwas 3-dodecylosulfanylomasłowy oraz zastosowania kwasu 3-dodecylosulfanylomasłowego do wytwarzania leku do zapobiegania insulinooporności.The subject of the application is 3-dodecylsulfanylbutyric acid for use as a medicine, especially for use in the treatment and prevention of the development of insulin resistance. The application also relates to a pharmaceutical composition characterized in that it contains 3-dodecylsulfanylbutyric acid as the active substance and the use of 3-dodecylsulfanylbutyric acid in the manufacture of a medicament for the prevention of insulin resistance.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL414785A PL228077B1 (en) | 2015-11-13 | 2015-11-13 | 3-dodecylsulfanyl-butyric acid to be used as a medicine, preferably to prevent development of insulin immunity and the composition containing 3-dodecylsulfanyl-butyric acid as active substance |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL414785A PL228077B1 (en) | 2015-11-13 | 2015-11-13 | 3-dodecylsulfanyl-butyric acid to be used as a medicine, preferably to prevent development of insulin immunity and the composition containing 3-dodecylsulfanyl-butyric acid as active substance |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL414785A1 true PL414785A1 (en) | 2017-05-22 |
| PL228077B1 PL228077B1 (en) | 2018-02-28 |
Family
ID=58709075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL414785A PL228077B1 (en) | 2015-11-13 | 2015-11-13 | 3-dodecylsulfanyl-butyric acid to be used as a medicine, preferably to prevent development of insulin immunity and the composition containing 3-dodecylsulfanyl-butyric acid as active substance |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL228077B1 (en) |
-
2015
- 2015-11-13 PL PL414785A patent/PL228077B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL228077B1 (en) | 2018-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018076601A2 (en) | oral pharmaceutical formulation, methods for treating a patient, and use of a formulation | |
| EA201591003A1 (en) | DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION | |
| EA201692301A1 (en) | DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION | |
| EA201401028A1 (en) | PHARMACEUTICAL COMPOSITION, CONTAINING EMAGOGLIFLOZIN AND MEDICINES FOR OBESITY | |
| EA201591004A1 (en) | DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION | |
| EA201590058A1 (en) | ANALOGUE GLUACAGONA | |
| EA201791333A1 (en) | GLUCAGON DERIVATIVES WITH IMPROVED STABILITY | |
| EA202090683A2 (en) | METHODS AND COMPOSITIONS FOR CANCER TREATMENT | |
| MX2017004772A (en) | Compositions and methods for physiological delivery using cannabidiol. | |
| EA201691918A1 (en) | PHARMACEUTICAL COMPOSITIONS OF KINAZ INHIBITOR KINAZ OF THE RAF FAMILY, METHODS OF THEIR PRODUCTION AND METHODS OF THEIR USE | |
| EA201692481A1 (en) | COMBINATION CONTAINING GLUCOCORTICOID AND EDO-S101 | |
| BR112017012406A2 (en) | fixed ratio formulation of insulin glargine / lixisenatide | |
| CY1122899T1 (en) | AQUEOUS FORMULATION INCLUDING PARACETAMOL AND IBUPROPHEN | |
| EA201591698A1 (en) | MACRO CYCLIC INHIBITORS OF KINASE LRRK2 | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| EA201591773A1 (en) | MACRO CYCLIC INHIBITORS RIP2-KINASE | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
| PH12017500323A1 (en) | P38 map kinase inhibiting indanyl urea compounds | |
| PL414785A1 (en) | 3-dodecylsulfanyl-butyric acid to be used as a medicine, preferably to prevent development of insulin immunity and the composition containing 3-dodecylsulfanyl-butyric acid as active substance | |
| TR201903234T4 (en) | Pharmaceutical solution containing dopamine for use in the treatment of Parkinson's disease. | |
| ES2422563A1 (en) | Injectable pharmaceutical composition of ibuprofen and arginine, its preparation procedure, unit dosage form and use thereof (Machine-translation by Google Translate, not legally binding) | |
| EA201650008A1 (en) | PHARMACEUTICAL COMPOSITION ON THE BASIS OF DIMETYLOXOBUTYL-PHOSPHONO DYMETHYLATE FOR INTERNAL APPLICATION (OPTIONS) | |
| EA201650009A1 (en) | PHARMACEUTICAL COMPOSITION FOR EXTERNAL APPLICATION BASED ON DIMETYLOXOBUTYL-PHOSPHONO DYMETHYLATE (OPTIONS) | |
| UA107884C2 (en) | Combined anti-tuberculosis drug |